BY EMMANUEL OGBONNA
Danish pharmaceutical giant Novo Nordisk is preparing to seek regulatory approval in China for its oral version of Wegovy, a move that could significantly expand its presence in one of the world’s fastest-growing obesity treatment markets and strengthen its position against increasingly aggressive competitors.
The company’s chief executive, Mike Doustdar, said the application for approval of the Wegovy weight-loss pill would be submitted to Chinese regulators in the coming months. The announcement signals Novo Nordisk’s determination to accelerate its growth strategy in China as competition in the obesity and diabetes treatment sector intensifies.
The race to develop and commercialize weight-loss pills has become one of the most important battles in the global pharmaceutical industry. While injectable treatments have transformed obesity care and generated billions of dollars in sales, drugmakers believe oral medications could unlock a much larger patient population by offering a more convenient alternative for individuals who are reluctant to use injections.
Novo Nordisk and its primary rival, Eli Lilly, are at the forefront of this competition. Both companies are investing heavily in expanding access to obesity treatments and developing next-generation medicines that can reach millions of new patients worldwide.
Speaking during his first visit to China since assuming leadership of Novo Nordisk in August, Doustdar expressed confidence that the company would soon advance the approval process for oral Wegovy. He indicated that regulatory submissions were expected within a relatively short timeframe, reflecting the strategic importance of the Chinese market to Novo Nordisk’s long-term plans.
China has emerged as a crucial battleground for pharmaceutical companies developing obesity treatments. Rising rates of obesity, increasing awareness of weight-related health risks, and growing consumer spending on healthcare have created substantial demand for innovative therapies. As a result, major international drugmakers and domestic biotechnology companies are competing aggressively for market share.
The competitive landscape has become increasingly crowded. Alongside Novo Nordisk and Eli Lilly, companies such as Pfizer and Innovent Biologics have entered the market, introducing new treatments and pursuing opportunities in the rapidly expanding obesity-care sector.
Novo Nordisk is also preparing for additional pressure from generic drug manufacturers. According to Doustdar, the company expects generic competition to begin emerging from the second quarter of next year, creating a new challenge for maintaining its market leadership.
One of the factors driving this shift is the expiration of the Chinese patent covering semaglutide, the active ingredient used in Novo Nordisk’s blockbuster drugs Wegovy and Ozempic. The patent expired in China in March, opening the door for future generic competition. However, Novo Nordisk continues to benefit from regulatory data protection that remains in effect until early next year, providing the company with a temporary layer of protection against copycat products.
Semaglutide has become one of the most successful pharmaceutical compounds in recent history. Originally developed for diabetes treatment, the drug gained worldwide attention after demonstrating significant weight-loss benefits. Its success has fueled enormous investor interest and transformed Novo Nordisk into one of Europe’s most valuable companies.
The company’s oral Wegovy formulation represents an important evolution of that success. By offering patients the option of a daily pill instead of a weekly injection, Novo Nordisk hopes to attract a broader group of consumers and healthcare providers. Industry analysts believe convenience could play a decisive role in the next phase of competition among obesity drug manufacturers.
Novo Nordisk has already achieved important regulatory milestones for the oral version of Wegovy. The treatment received early approvals in both the United States and the United Kingdom, and the company launched the medication in the U.S. market this year. Those approvals have strengthened confidence that the drug could gain acceptance in other major markets, including China.
Eli Lilly has moved quickly to challenge Novo Nordisk’s dominance. The company secured U.S. approval in April for its oral obesity treatment, known as orforglipron, marking a major milestone in the competition between the two pharmaceutical giants.
In China, however, Eli Lilly has gained an early advantage. The company announced earlier that it had submitted a marketing application for once-daily orforglipron to Chinese regulators, positioning itself ahead of Novo Nordisk in the race for approval of oral obesity medicines in the country.
Both Wegovy and orforglipron belong to the rapidly growing class of drugs known as GLP-1 therapies. These medications work by mimicking naturally occurring hormones that help regulate appetite, blood sugar levels, and digestion. Their effectiveness in helping patients lose weight has made them some of the most sought-after treatments in modern medicine.
Despite the growing popularity of these therapies, the true size of China’s obesity drug market remains difficult to determine. Many pharmaceutical companies operating in the sector do not publicly disclose detailed sales figures, making it challenging to assess market shares and competitive positioning.
However, available data suggest demand is rising rapidly. According to estimates from investment bank Jefferies, sales of GLP-1 medications through major Chinese e-commerce platforms operated by Alibaba Group and JD.com reached approximately 1.4 billion yuan, or about $207 million, during the first quarter alone.
The strong sales performance highlights the growing appetite among Chinese consumers for advanced weight-management treatments and underscores why global pharmaceutical companies view the market as a key growth opportunity.
As Novo Nordisk prepares its regulatory submission, the company faces a critical period in China. Success could strengthen its position in one of the world’s largest healthcare markets and help defend its leadership in the rapidly expanding obesity treatment sector. At the same time, increasing competition from multinational rivals, domestic biotech firms, and future generic manufacturers ensures that the battle for China’s weight-loss drug market is likely to become even more intense in the years ahead.
Original article
Comments